A Phase 2 interventional study of VIB4920 and Placebo in Rheumatoid Arthritis, sponsored by Amgen. Completed at 25 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-12-17.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Arthritis, Rheumatoid by Amgen — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Amgen.
Among the 57 studies in Arthritis, Rheumatoid by Amgen, this one is the 34th largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2019, is one of 14 in phase 2, and was the 56th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →1 of the 57 studies in Arthritis, Rheumatoid by Amgen is open now, in 10 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Australia, Belgium and 7 more countries
Ages 18–75
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 17 · Phase 3 17 · Phase 4 12
First in 1997; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 211 across the 47 interventional studies, 2,522 across the 4 observational. Of the 56 that completed or were terminated, 30 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 57 studies in Arthritis, Rheumatoid by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of VIB4920 (formerly MEDI4920) in adult participants with rheumatoid arthritis (RA).
The overall study period will be approximately 337 days. After a screening period of up to 28 days, the participants will be randomized in a 1:1:1:1:1 ratio to receive intravenous dose of VIB4920 and/or placebo in 5 cohorts. Participants are to be followed on their stable background anti-RA therapy at least through 12 weeks (Day 85), at which time rescue therapy may be instituted. All participants will be followed at least through the primary (interim) analysis (Day 113), and those who have not instituted rescue therapy will be followed through Day 309 to determine the duration of clinical response. The primary analysis will be after all participants have completed Day 113, and the final analysis will be after all participants have completed follow-up.
Study with completed results acquired from Horizon in 2024.
Principal Inclusion Criteria:
Principal Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive intravenous (IV) infusion of VIB4920 1500 mg on Days 1, 15, 29, and 57
Drug: VIB4920
Participants receive IV infusion of VIB4920 1500 mg on Days 1 and 57, placebo on Days 15 and 29.
Drug: VIB4920 · Drug: Placebo
Participants receive IV infusion of VIB4920 3000 mg on Days 1 and 57, placebo on Days 15 and 29.
Drug: VIB4920 · Drug: Placebo
Participants receive IV infusion of VIB4920 3000 mg on Day 1 and placebo on Days 15, 29, and 57.
Drug: VIB4920 · Drug: Placebo
Participants receive IV infusion of placebo matched to VIB4920 on Days 1, 15, 29, and 57.
Drug: Placebo
liquid for IV infusion following dilution in normal saline
Also known as: MEDI4920, dazodalibep
0.9% saline for IV infusion
Change From Baseline to Day 113 in DAS28-CRP
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline indicates improvement in disease activity. Results are from a mixed-effect model for repeated measures (MMRM) analysis with treatment, visit, visit by treatment interaction, and baseline DAS28-CRP score included in the model.
Time frame: Day 1 (Baseline), Day 113
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Treatment-emergent Adverse Events of Special Interest (TEAESIs)
Adverse event (AE): any untoward medical occurrence associated with the use of an intervention in humans, whether or not it is considered intervention-related. Serious adverse event (SAE): an AE that results in any of the following outcomes: death; life-threatening AE; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant incapacity; congenital anomaly/birth defect; other important medical event jeopardizing the participant's well-being. AEs of special interest (AESIs) include: thrombotic and embolic events; anaphylaxis and clinically significant (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade 3 or higher) hypersensitivity reactions; severe infusion-related reactions (CTCAE Grade 3 or higher); immune complex disease; severe (CTCAE Grade 3 or higher) and/or opportunistic infections; hepatic function abnormality meeting the definition of Hy's Law; malignant neoplasm. (CTCAE Grade 3=Severe; Grade 4=Life-threatening; Grade 5=Fatal.)
Time frame: From first dose of study drug through Day 309 ± 7 days
Pharmacokinetics (PK) of VIB4920: Maximum Observed Concentration (Cmax)
Time frame: Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d
PK of VIB4920: Time to Cmax (Tmax)
Time frame: Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d
PK of VIB4920: Area Under the Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast)
Time frame: Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d
PK of VIB4920: Area Under the Concentration-Time Curve From Time 0 to Day 56 (AUC0-56D)
Time frame: Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), Day 56
PK of VIB4920: Total Body Clearance (CL) for Dose 1 and Total Body Clearance at Steady State (CLss) for Doses 2 to 4
Time frame: Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d
PK of VIB4920: Terminal Elimination Half-Life (t1/2)
Time frame: Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d
PK of VIB4920: Volume of Distribution at Steady State (Vss)
Time frame: Predose (within 30 minutes prior to start of infusion), and within 10 minutes of the end of infusion on Days 1 (Dose 1), 15 ± 1 day (d; Dose 2), 29 ± 3d (Dose 3), 57 ± 3d (Dose 4), and Days 85 ± 3d, 113 ± 5d, 141 ± 5d, 169 ± 5d, 197 ± 7d, 225 ± 7d
Total Soluble Cluster of Differentiation 40 Ligand (sCD40L) Plasma Concentration Over Time
Total sCD40L (free sCD40L and sCD40L bound to VIB4920) was measured in plasma samples using a modified commercially available kit.
Time frame: Day 1 (Baseline), Days 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309
Percentage of Participants With Positive Anti-Drug Antibodies (ADA) to VIB4920
ADA positive at any time: observed at least once during the study (baseline included). Treatment-emergent ADA: ADA positive post-baseline only or boosted pre-existing ADA during the study period. Persistent positive: treatment-induced ADA positive at ≥ 2 post-baseline assessments (with ≥ 16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive: treatment-induced ADA post-baseline positive but does not fulfill the criteria of persistent positive.
Time frame: Day 1 (Baseline) to Day 309 Day 1 (Baseline) up to Day 309 (± 7 days)
Change From Baseline to Day 113 in Anti-Citrullinated Protein Antibodies (ACPAs)
Excluding data after rescue. Adjusted geometric mean ratio to baseline (90% CI) results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model. Ratios less than 1 indicate a decrease.
Time frame: Day 1 (Baseline), Day 113
Change From Baseline to Day 113 in Rheumatoid Factor (RF)
Excluding data after rescue. Adjusted geometric mean ratio to baseline (90% CI) results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model. Ratios less than 1 indicate a decrease.
Time frame: Day 1 (Baseline), Day 113
Percentage of Participants With Clinical Remission at Day 113
Clinical remission is defined as DAS28-CRP \< 2.6. The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity.
Time frame: Day 113
Time to Start of New Treatment for Rheumatoid Arthritis (Rescue Medication)
Based on Kaplan-Meier method.
Time frame: Day 1 (Baseline) up to Day 309 (± 7 days)
| Milestone | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|---|
| Started | 16 | 16 | 16 | 15 | 15 |
| Completed | 15 | 13 | 11 | 12 | 14 |
| Not completed | 1 | 3 | 5 | 3 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 3 | 1 | 1 |
| Withdrew: Other, not specified | 0 | 1 | 1 | 1 | 0 |
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline indicates improvement in disease activity. Results are from a mixed-effect model for repeated measures (MMRM) analysis with treatment, visit, visit by treatment interaction, and baseline DAS28-CRP score included in the model.
| score on a scale | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|---|
| Change From Baseline to Day 113 in DAS28-CRP | -1.06 ± 0.26 | -1.90 ± 0.27 | -1.87 ± 0.27 | -1.87 ± 0.27 | -1.83 ± 0.28 |
Adverse event (AE): any untoward medical occurrence associated with the use of an intervention in humans, whether or not it is considered intervention-related. Serious adverse event (SAE): an AE that results in any of the following outcomes: death; life-threatening AE; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant incapacity; congenital anomaly/birth defect; other important medical event jeopardizing the participant's well-being. AEs of special interest (AESIs) include: thrombotic and embolic events; anaphylaxis and clinically significant (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade 3 or higher) hypersensitivity reactions; severe infusion-related reactions (CTCAE Grade 3 or higher); immune complex disease; severe (CTCAE Grade 3 or higher) and/or opportunistic infections; hepatic function abnormality meeting the definition of Hy's Law; malignant neoplasm. (CTCAE Grade 3=Severe; Grade 4=Life-threatening; Grade 5=Fatal.)
| Participants | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|---|
| At least one event | 10 | 10 | 14 | 11 | 11 |
| At least one study drug-related event | 4 | 3 | 4 | 2 | 2 |
| At least one event of ≥ Grade 3 severity | 0 | 1 | 1 | 0 | 0 |
| Death (Grade 5 severity) | 0 | 0 | 1 | 0 | 0 |
| At least one serious event | 0 | 1 | 1 | 0 | 1 |
| At least one serious and/or ≥ Grade 3 severity event | 0 | 1 | 1 | 0 | 0 |
| At least one related serious event | 0 | 0 | 0 | 0 | 0 |
| At least one event leading to discontinuation of study drug | 0 | 1 | 0 | 0 | 0 |
| At least one event of special interest | 0 | 1 | 1 | 0 | 0 |
| μg/mL | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|
| Dose 1 | 877 ± 204 | 476 ± 127 | 860 ± 275 | 421 ± 102 |
| Dose 2 | — | 504 ± 162 | 1050 ± 349 | 564 ± 163 |
| Dose 3 | — | — | — | 601 ± 181 |
| Dose 4 | — | — | — | 568 ± 140 |
| day | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|
| Dose 1 | 0.0899 (0.0868 to 0.100) | 0.0875 (0.0847 to 0.0951) | 0.0875 (0.0840 to 0.0917) | 0.0903 (0.0840 to 0.108) |
| Dose 2 | — | 0.0681 (0.0646 to 0.0847) | 0.0667 (0.0486 to 0.0882) | 0.0486 (0.0437 to 0.0521) |
| Dose 3 | — | — | — | 0.0472 (0.0438 to 0.0486) |
| Dose 4 | — | — | — | 0.0667 (0.0486 to 0.0708) |
| μg·day/mL | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|
| Dose 1 | 7350 ± 1380 | 3980 ± 1580 | 7870 ± 2570 | 2960 ± 604 |
| Dose 2 | — | 5280 ± 2000 | 10000 ± 3320 | 4060 ± 1290 |
| Dose 3 | — | — | — | 6350 ± 1840 |
| Dose 4 | — | — | — | 5770 ± 1110 |
| μg·day/mL | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|
| Dose 1 | 7280 ± 1370 | 4280 ± 1280 | 7870 ± 2570 | — |
| Dose 2 | — | 5310 ± 2000 | 9910 ± 3250 | — |
| mL/day | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|
| Dose 1 (CL) | 430 ± 91.9 | 371 ± 92.5 | 417 ± 144 | — |
| Dose 2 (CLss) | — | 314 ± 104 | 340 ± 140 | — |
| Dose 4 (CLss) | — | — | — | 294 ± 49.8 |
| day | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|
| Dose 1 | 9.27 ± 1.61 | 9.06 ± 1.98 | 9.02 ± 1.06 | — |
| Dose 2 | — | 9.55 ± 1.51 | 9.88 ± 1.41 | — |
| Dose 4 | — | — | — | 10.5 ± 2.06 |
| mL | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|
| Dose 1 | 4350 ± 1300 | 3750 ± 601 | 4540 ± 1470 | — |
| Dose 2 | — | 3490 ± 926 | 3600 ± 1720 | — |
| Dose 4 | — | — | — | 3210 ± 865 |
Total sCD40L (free sCD40L and sCD40L bound to VIB4920) was measured in plasma samples using a modified commercially available kit.
| ng/mL | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|---|
| Change at Day 15 | 4.6759 ± 3.6596 | 30.7744 ± 7.4954 | 36.0088 ± 14.4324 | 28.2492 ± 10.4252 | 33.9007 ± 8.7777 |
| Change at Day 29 | 4.8431 ± 3.3770 | 67.5427 ± 16.4322 | 66.7047 ± 15.3708 | 68.0636 ± 28.6523 | 68.1386 ± 12.1314 |
| Change at Day 57 | 0.8150 ± 1.6053 | 64.4177 ± 16.4322 | 62.5560 ± 14.4445 | 63.6939 ± 25.5500 | 64.1329 ± 12.4842 |
| Change at Day 85 | 0.4483 ± 1.1842 | 53.1583 ± 20.6513 | 77.5360 ± 18.7440 | 57.2587 ± 20.0742 | 69.8821 ± 19.2623 |
| Change at Day 113 | 0.3420 ± 1.3246 | 21.4686 ± 19.3705 | 75.4407 ± 18.2921 | 53.4514 ± 26.2712 | 68.5636 ± 19.3458 |
| Change at Day 141 | 0.2547 ± 0.9863 | 1.6517 ± 3.7565 | 55.4204 ± 28.9470 | 53.2827 ± 31.6165 | 52.3943 ± 29.4422 |
| Change at Day 169 | 0.3114 ± 1.1653 | 0 ± 0 | 21.1296 ± 27.1973 | 18.3170 ± 20.2842 | 23.5727 ± 26.0510 |
| Change at Day 197 | 0.2757 ± 1.0316 | 0 ± 0 | 4.4354 ± 9.9146 | 2.5057 ± 4.4880 | 4.6343 ± 5.3603 |
| Change at Day 225 | 0.2450 ± 0.9167 | 0 ± 0 | -0.4043 ± 1.5127 | -0.0137 ± 1.1940 | -0.2971 ± 0.8718 |
| Change at Day 253 | 0.3436 ± 1.2855 | 3.1418 ± 11.7555 | -0.5946 ± 2.1439 | -0.5292 ± 1.9082 | -0.9485 ± 2.3281 |
| Change at Day 281 | -0.0343 ± 0.1283 | 0 ± 0 | -0.5640 ± 1.7835 | -0.4729 ± 1.7693 | -0.9485 ± 2.3281 |
| Change at Day 309 | -0.5654 ± 2.1154 | 0 ± 0 | -0.5720 ± 1.8088 | -0.7833 ± 2.7135 | -0.9485 ± 2.3281 |
ADA positive at any time: observed at least once during the study (baseline included). Treatment-emergent ADA: ADA positive post-baseline only or boosted pre-existing ADA during the study period. Persistent positive: treatment-induced ADA positive at ≥ 2 post-baseline assessments (with ≥ 16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive: treatment-induced ADA post-baseline positive but does not fulfill the criteria of persistent positive.
| percentage of participants | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|
| ADA positive at any time | 44.4 | 11.8 | 38.5 | 28.6 |
| Baseline ADA positive | 0 | 0 | 0 | 0 |
| Baseline only ADA positive | 0 | 0 | 0 | 0 |
| Post-baseline ADA positive | 44.4 | 11.8 | 38.5 | 28.6 |
| Treatment-emergent ADA | 44.4 | 11.8 | 38.5 | 28.6 |
| Persistent positive | 11.1 | 0 | 0 | 0 |
| Transient positive | 33.3 | 11.8 | 38.5 | 28.6 |
Excluding data after rescue. Adjusted geometric mean ratio to baseline (90% CI) results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model. Ratios less than 1 indicate a decrease.
| ratio | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|---|
| Change From Baseline to Day 113 in Anti-Citrullinated Protein Antibodies (ACPAs) | 1.08 (0.83 to 1.42) | 0.69 (0.52 to 0.91) | 0.82 (0.62 to 1.07) | 0.84 (0.63 to 1.11) | 0.62 (0.47 to 0.82) |
Excluding data after rescue. Adjusted geometric mean ratio to baseline (90% CI) results are from MMRM analysis on log(ratio to baseline) with treatment, visit, visit by treatment interaction, and log(baseline) included in the model. Ratios less than 1 indicate a decrease.
| ratio | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|---|
| Change From Baseline to Day 113 in Rheumatoid Factor (RF) | 1.20 (1.04 to 1.39) | 0.77 (0.66 to 0.89) | 0.74 (0.64 to 0.86) | 0.72 (0.62 to 0.84) | 0.57 (0.49 to 0.66) |
Clinical remission is defined as DAS28-CRP \< 2.6. The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity.
| percentage of participants | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|---|
| Percentage of Participants With Clinical Remission at Day 113 | 18.8 | 18.8 | 6.3 | 13.3 | 13.3 |
Based on Kaplan-Meier method.
| days | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|---|
| Time to Start of New Treatment for Rheumatoid Arthritis (Rescue Medication) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (196 to NA) |
Collected over From screening (all cause mortality) or first dose of study drug (adverse events) through through Day 309 ± 7 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/16 (0%) | 0/16 (0%) | 10/16 (62.5%) |
| VIB4920 3000 mg Once | 0/18 (0%) | 1/18 (5.6%) | 10/18 (55.6%) |
| VIB4920 1500 mg Twice | 1/17 (5.9%) | 1/17 (5.9%) | 14/17 (82.4%) |
| VIB4920 3000 mg Twice | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| VIB4920 1500 mg 4 Times | 0/14 (0%) | 1/14 (7.1%) | 10/14 (71.4%) |
| Event | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|---|
| NephrolithiasisRenal and urinary disorders | 0/16 | 0/18 | 0/17 | 0/13 | 1/14 |
| DeathGeneral disorders | 0/16 | 0/18 | 1/17 | 0/13 | 0/14 |
| COVID-19 pneumoniaInfections and infestations | 0/16 | 0/18 | 1/17 | 0/13 | 0/14 |
| COVID-19Infections and infestations | 0/16 | 1/18 | 0/17 | 0/13 | 0/14 |
| Event | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times |
|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/16 | 1/18 | 0/17 | 3/13 | 0/14 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/16 | 0/18 | 0/17 | 3/13 | 0/14 |
| COVID-19Infections and infestations | 1/16 | 1/18 | 3/17 | 0/13 | 3/14 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 1/16 | 0/18 | 3/17 | 2/13 | 1/14 |
| PharyngitisInfections and infestations | 0/16 | 0/18 | 0/17 | 2/13 | 1/14 |
| CystitisInfections and infestations | 2/16 | 0/18 | 0/17 | 0/13 | 1/14 |
| Urinary tract infectionInfections and infestations | 2/16 | 0/18 | 1/17 | 0/13 | 0/14 |
| LymphopeniaBlood and lymphatic system disorders | 0/16 | 0/18 | 2/17 | 0/13 | 0/14 |
| Alanine aminotransferase increasedInvestigations | 0/16 | 1/18 | 2/17 | 1/13 | 0/14 |
| Aspartate aminotransferase increasedInvestigations | 0/16 | 0/18 | 2/17 | 0/13 | 0/14 |
Full Analysis Set: all randomized participants who received any dose of study drug, analyzed according to the treatment randomized.
| Age, Continuous(years) | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times | Total |
|---|---|---|---|---|---|---|
| Mean | 56.3 ± 14.0 | 53.2 ± 10.7 | 59.0 ± 12.2 | 56.5 ± 12.2 | 56.4 ± 15.2 | 56.3 ± 12.7 |
| Sex: Female, Male(Participants) | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times | Total |
|---|---|---|---|---|---|---|
| Female | 12 | 14 | 11 | 13 | 12 | 62 |
| Male | 4 | 2 | 5 | 2 | 3 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 1 | 0 | 0 | 3 |
| Not Hispanic or Latino | 15 | 15 | 15 | 15 | 15 | 75 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times | Total |
|---|---|---|---|---|---|---|
| Black or African American | 2 | 0 | 0 | 1 | 1 | 4 |
| White | 14 | 16 | 15 | 14 | 14 | 73 |
| Other, Not Specified | 0 | 0 | 1 | 0 | 0 | 1 |
| Disease Activity Score 28 C-reactive Protein (DAS28-CRP)(score on a scale) | Placebo | VIB4920 3000 mg Once | VIB4920 1500 mg Twice | VIB4920 3000 mg Twice | VIB4920 1500 mg 4 Times | Total |
|---|---|---|---|---|---|---|
| Mean | 5.443 ± 1.066 | 5.473 ± 0.883 | 5.945 ± 0.736 | 5.452 ± 0.644 | 5.761 ± 0.711 | 5.615 ± 0.830 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Dec 2021, 24 months.
Results were first posted in Feb 2023, 1 year 1 month after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 24 months is above that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dazodalibep